- Home
- UFPI vs ACAD Comparison
UFPI vs ACAD Comparison
Compare UFPI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UFPI | ACAD |
|---|---|---|
| Founded | 1955 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.6B |
| IPO Year | 1993 | 2004 |
Fundamental Metrics
Financial Performance| Metric | UFPI | ACAD |
|---|---|---|
| Price | $91.55 | $27.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 23 |
| Target Price | ★ $114.00 | $29.39 |
| AVG Volume (30 Days) | 484.1K | ★ 1.6M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | ★ 98.53 |
| EPS | ★ 5.39 | 1.54 |
| Revenue | ★ $6,452,521,000.00 | $1,047,118,000.00 |
| Revenue This Year | N/A | $15.16 |
| Revenue Next Year | $2.12 | $11.51 |
| P/E Ratio | ★ $17.19 | $18.21 |
| Revenue Growth | N/A | ★ 12.69 |
| 52 Week Low | $87.11 | $13.40 |
| 52 Week High | $120.00 | $28.26 |
Technical Indicators
Market Signals| Indicator | UFPI | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 48.60 | 68.03 |
| Support Level | $90.93 | $26.56 |
| Resistance Level | $95.22 | $27.47 |
| Average True Range (ATR) | 2.03 | 0.87 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 52.32 | 83.56 |
Price Performance
Historical ComparisonAbout UFPI UFP Industries Inc.
UFP Industries Inc is a supplier of lumber to the manufactured housing industry. Today UFP Industries is a multibillion-dollar holding company with subsidiaries around the globe that serve three markets: retail, packaging and construction. Its business segments consist of UFP Retail Solutions, UFP Packaging, UFP Construction, All other and Corporate.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.